Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540303 | 1.00 | CCR5 (0.45) | CCR5NR1H2NR1H3GPR119HCRTR2 | |
| SCHEMBL696712 | 0.90 | CCR5 (0.45) | CCR5NR1H2NR1H3GPR119HCRTR2 | |
| SCHEMBL15000993 | 0.79 | GPR119 (0.64) | GPR119NPC1HTT | |
| SCHEMBL17754587 | 0.78 | GPR119 (0.49) | NR1H2GPR119MEN1KMT2ACYP2D6 | |
| SCHEMBL2381394 | 0.78 | AGTR2 (0.48) | CCR5NR1H2NR1H3GPR119HCRTR2 | |
| SCHEMBL1983287 | 0.78 | AGTR2 (0.48) | CCR5NR1H2NR1H3GPR119HCRTR2 | |
| SCHEMBL1984795 | 0.78 | AGTR2 (0.48) | CCR5NR1H2NR1H3GPR119HCRTR2 | |
| SCHEMBL4956504 | 0.76 | TSHR (0.44) | HCRTR2MEN1KMT2A | |
| SCHEMBL4956510 | 0.76 | TSHR (0.44) | HCRTR2MEN1KMT2A | |
| SCHEMBL18271394 | 0.75 | SLC6A9 (0.56) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | CCR5 3021/4885NR1H2 719/4885NR1H3 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.